EW Edwards Lifesciences

company

SEC Filings & Insider Trading Activity 2026

Management Discussion & Analysis

• • Revenue $6.07B, up $628.1M (+11.5% YoY); TMTT best-performing segment +56.4% to $550.6M; Surgical weakest at +4.9% to $1.03B
• • Gross profit as % of net sales decreased due to higher operational expenses; litigation expenses surged to $325.4M in 2025 vs $40.4M in 2024; effective tax rate 17.0% vs 9.8%
• • Operating cash flow $1.60B, up $1.05B YoY; capex $260.2M in 2025, guided ~$280M in 2026
• • Share buybacks $884.7M (11.7M shares) in 2025; $2.0B repurchase authority remaining; no dividends mentioned; $600M senior notes due 2028 outstanding
• • Key risks: IRS transfer pricing dispute ($269.3M additional tax claimed), Pillar Two added $19.1M tax expense, and ongoing IP litigation

Business Overview

• • Structural heart pure-play: TAVR, TMTT, and Surgical segments targeting aortic, mitral, tricuspid, and pulmonic valve disease
• • TMTT fastest-growing segment: revenue share expanded to 9% in FY2025 vs 7% in FY2024 and 4% in FY2023
• • KONECT RESILIA aortic valved conduit launched in Europe in 2025; EARLY TAVR trial 2024 data supporting asymptomatic aortic stenosis indication expansion
• • R&D spend ~18% of 2025 sales, up ~2% YoY; ~16,000 employees worldwide as of December 31, 2025
• • TAVR share of net sales declined to 74% in FY2025 from 77% in FY2023, reflecting deliberate portfolio diversification toward TMTT

Risk Factors

• • Section 232 investigation by U.S. Dept. of Commerce into medical device imports could impose tariffs, raising manufacturing costs and disrupting Edwards' supply chain
• • EU MDR compliance risk: unresolved EU-Switzerland Mutual Recognition Agreement may block Edwards from placing devices on EU market via Swiss operations
• • Single-source supplier dependency for key materials; regulatory burden of FDA qualification makes replacement difficult and costly
• • Competitors introducing new TAVR/TMTT technologies competing for same hospital catheterization labs, directly constraining Edwards' procedure volumes
• • GDPR, HIPAA, and CCPA compliance exposure across multiple jurisdictions; GDPR noncompliance penalties and CCPA private right of action create layered financial liability

What are the latest EW SEC filings in 2026?

Edwards Lifesciences (EW) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on July 23, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did EW file its most recent 10-K annual report?

Edwards Lifesciences (EW) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view EW 10-Q quarterly reports?

Edwards Lifesciences (EW)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every EW 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has EW filed recently?

Edwards Lifesciences (EW)'s most recent 8-K was filed on July 23, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find EW insider trading activity (Form 4)?

SignalX aggregates every EW Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does EW file with the SEC?

Edwards Lifesciences (EW) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new EW filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Edwards Lifesciences (EW).

What is EW's SEC CIK number?

Edwards Lifesciences (EW)'s SEC CIK (Central Index Key) number is 1099800. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1099800 to look up all EW filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find EW return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Edwards Lifesciences (EW) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.